Valsartan/sacubitril, insuffisance cardiaque aigue, Dr Philippe Meyer, 26.02.19

Menu

1. Valsartant/sacubitril aussi dans l'insuffisance cardiaque aigue
2. Angiotensin-Neprilysin Inhibiton in Acute Decompensated Heart Failure
3. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
4. ARNI= Angiotensin receptor-neprilysin inhibitor
5. Neprilysin inhibition
6. Primary endpoint: CV mortality + HF hospitalizations
7. 2016 ESC Guidelines
8. First step: ACEi, BB, diuretics
9. Angiotensin receptor Neprilysin Inhibition
10. Angiotensin-Neprilysin Inhibiton in Acute Decompensated Heart Failure
11. Methods
12. Baseline characteristics
13. Primary endpoint: % change in NT-proBNP
14. Safety events
15. Results
16. Exploratory serious clinical composite endpoint
17. Conclusions
18. Which HF patients should not receive sacubitril/valsartan?
19. MERCI!
20. Médicaments
21. Conflits d’intérêt potentiels
22. NT-proBNP: a powerful independent predictor of mortality in HF
23. NPPB gene

FINISH

SUBMIT

NEXT

PREV